Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab with metronomic vinorelbine in previously treated advanced squamous NSCLC
ChiCTR2500100631Phase 4Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Apr 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab, tuvonralimab and vinorelbine in non-small cell lung cancer (NSCLC) and Pulmonary squamous cell carcinoma, sponsored by Sichuan Cancer Hospital. Primary endpoints: Recommended Phase II dose and Objective response rate. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabvinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2500100631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100631.